Literature DB >> 18986838

The complex role of B7 molecules in tumor immunology.

Barbara Seliger1, Francesco M Marincola, Soldano Ferrone, Hinrich Abken.   

Abstract

T-cell activation requires the interaction of the T-cell receptor with a cognate major histocompatibility complex (MHC)-peptide complex. Initiated by antigen engagement, the adaptive immune response is orchestrated by a complex balance between stimulatory and inhibitory signals that are predominantly controlled by members of the B7 family. Here, we review the current knowledge on B7 family members concerning their constitutive and regulated expression, modulation of the immune response and their role in the evasion of host immune surveillance. We also discuss recent therapeutic strategies that aim to improve immune-cell recognition of tumors and induce tolerance to autoreactive immune responses in normal tissues by manipulating B7 functions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18986838      PMCID: PMC2726789          DOI: 10.1016/j.molmed.2008.09.010

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  110 in total

1.  Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS.

Authors:  S Wang; G Zhu; A I Chapoval; H Dong; K Tamada; J Ni; L Chen
Journal:  Blood       Date:  2000-10-15       Impact factor: 22.113

Review 2.  The B7-CD28 superfamily.

Authors:  Arlene H Sharpe; Gordon J Freeman
Journal:  Nat Rev Immunol       Date:  2002-02       Impact factor: 53.106

3.  ICOS co-stimulatory receptor is essential for T-cell activation and function.

Authors:  C Dong; A E Juedes; U A Temann; S Shresta; J P Allison; N H Ruddle; R A Flavell
Journal:  Nature       Date:  2001-01-04       Impact factor: 49.962

4.  B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production.

Authors:  A I Chapoval; J Ni; J S Lau; R A Wilcox; D B Flies; D Liu; H Dong; G L Sica; G Zhu; K Tamada; L Chen
Journal:  Nat Immunol       Date:  2001-03       Impact factor: 25.606

5.  PD-L2 is a second ligand for PD-1 and inhibits T cell activation.

Authors:  Y Latchman; C R Wood; T Chernova; D Chaudhary; M Borde; I Chernova; Y Iwai; A J Long; J A Brown; R Nunes; E A Greenfield; K Bourque; V A Boussiotis; L L Carter; B M Carreno; N Malenkovich; H Nishimura; T Okazaki; T Honjo; A H Sharpe; G J Freeman
Journal:  Nat Immunol       Date:  2001-03       Impact factor: 25.606

Review 6.  The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses.

Authors:  Beatriz M Carreno; Mary Collins
Journal:  Annu Rev Immunol       Date:  2001-10-04       Impact factor: 28.527

7.  Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma.

Authors:  Scott J Antonia; John Seigne; Jose Diaz; Carlos Muro-Cacho; Martine Extermann; Mary Jane Farmelo; Maria Friberg; Marwan Alsarraj; J J Mahany; Julio Pow-Sang; Alan Cantor; William Janssen
Journal:  J Urol       Date:  2002-05       Impact factor: 7.450

8.  PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2.

Authors:  LauraL Carter; Lynette A Fouser; Jason Jussif; Lori Fitz; Bija Deng; Clive R Wood; Mary Collins; Tasuku Honjo; Gordon J Freeman; Beatriz M Carreno
Journal:  Eur J Immunol       Date:  2002-03       Impact factor: 5.532

9.  Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.

Authors:  G J Freeman; A J Long; Y Iwai; K Bourque; T Chernova; H Nishimura; L J Fitz; N Malenkovich; T Okazaki; M C Byrne; H F Horton; L Fouser; L Carter; V Ling; M R Bowman; B M Carreno; M Collins; C R Wood; T Honjo
Journal:  J Exp Med       Date:  2000-10-02       Impact factor: 14.307

10.  B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells.

Authors:  S Y Tseng; M Otsuji; K Gorski; X Huang; J E Slansky; S I Pai; A Shalabi; T Shin; D M Pardoll; H Tsuchiya
Journal:  J Exp Med       Date:  2001-04-02       Impact factor: 14.307

View more
  27 in total

1.  The expressions and significance of B7-H3 and CTLA-4 in the clinical stages of non-small-cell lung cancer.

Authors:  Zheng Liu; Meng-Miao Pei; Jun-Xia Liu; Fang Shi; Ye Zhang; Dong-Fang Zhao; Jian-Ming Li; Feng-Rui Guo; Jing-Jing Yan; Jia-Qi Liu; Yin-Peng Li
Journal:  Int J Clin Exp Pathol       Date:  2019-08-01

2.  CD86 gene variants and susceptibility to pancreatic cancer.

Authors:  Honggang Xiang; Wei Zhao; Yanping Sun; Winnie Qian; Junjie Xing; Yujia Zhou; Jun Yao; Jian Xu; Yi Wang; Houshan Yao; Zhiqian Hu
Journal:  J Cancer Res Clin Oncol       Date:  2012-07-21       Impact factor: 4.553

Review 3.  Location, location, location: functional and phenotypic heterogeneity between tumor-infiltrating and non-infiltrating myeloid-derived suppressor cells.

Authors:  Sarah K Maenhout; Kris Thielemans; Joeri L Aerts
Journal:  Oncoimmunology       Date:  2014-12-15       Impact factor: 8.110

4.  Molecular mechanisms of TNFR-associated factor 6 (TRAF6) utilization by the oncogenic viral mimic of CD40, latent membrane protein 1 (LMP1).

Authors:  Kelly M Arcipowski; Laura L Stunz; John P Graham; Zachary J Kraus; Tony J Vanden Bush; Gail A Bishop
Journal:  J Biol Chem       Date:  2011-01-24       Impact factor: 5.157

5.  Expression and clinical significance of programmed death ligand 1 in nasopharyngeal carcinoma.

Authors:  Yuan Qu; Di Wang; Lin Yang; Hui-Ying Liu; Wei Cui; Yi-Qun Che
Journal:  Mol Clin Oncol       Date:  2018-05-21

Review 6.  Targeting inhibitory pathways in cancer immunotherapy.

Authors:  Marcio O Lasaro; Hildegund C J Ertl
Journal:  Curr Opin Immunol       Date:  2010-05-12       Impact factor: 7.486

7.  Impact of neoadjuvant chemotherapy on lymphocytes and co-inhibitory B7-H4 molecule in gastric cancer: low B7-H4 expression associates with favorable prognosis.

Authors:  Ninu Maskey; Kai Li; Min Hu; Zhigao Xu; Chunwei Peng; Fang Yu; Hong Cao; Jiamei Chen; Yan Li; Guifang Yang
Journal:  Tumour Biol       Date:  2014-09-27

8.  Comprehensive molecular profiling of the B7 family of immune-regulatory ligands in breast cancer.

Authors:  Zhenyu Xu; Jing Shen; Maggie Haitian Wang; Tao Yi; Yangyang Yu; Yinxin Zhu; Bo Chen; Jianping Chen; Longfei Li; Minxing Li; Jian Zuo; Hui Jiang; Dexi Zhou; Jiajie Luan; Zhangang Xiao
Journal:  Oncoimmunology       Date:  2016-07-11       Impact factor: 8.110

9.  B7-H4 overexpression correlates with a poor prognosis for cervical cancer patients.

Authors:  Wenting Liu; Kiyosumi Shibata; Yoshihiro Koya; Hiroaki Kajiyama; Takeshi Senga; Mamoru Yamashita; Fumitaka Kikkawa
Journal:  Mol Clin Oncol       Date:  2013-12-12

10.  VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy.

Authors:  J Louise Lines; Lorenzo F Sempere; Thomas Broughton; Li Wang; Randolph Noelle
Journal:  Cancer Immunol Res       Date:  2014-06       Impact factor: 11.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.